Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 3
1988 4
1989 3
1990 1
1991 1
1992 4
1993 7
1994 8
1995 6
1996 7
1997 11
1998 9
1999 6
2000 6
2001 6
2002 2
2003 7
2004 1
2005 1
2006 4
2007 4
2008 8
2009 4
2010 3
2011 4
2012 5
2013 5
2014 3
2015 2
2016 2
2017 2
2018 4
2019 3
2020 1
2021 1
2022 2
2023 1
2024 5
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.
Lehr T, Meiser P, Selzer D, Rixecker T, Holzer F, Mösges R, Smola S, Bals R; CONTAIN Study Group. Lehr T, et al. JAMA Intern Med. 2025 Nov 1;185(11):1309-1317. doi: 10.1001/jamainternmed.2025.4283. JAMA Intern Med. 2025. PMID: 40892398 Free PMC article. Clinical Trial.
CONCLUSIONS AND RELEVANCE: In this single-center trial, azelastine nasal spray was associated with reduced risk of SARS-CoV-2 respiratory infections. These findings support the potential of azelastine as a safe prophylactic approach warranting confirmation in larger …
CONCLUSIONS AND RELEVANCE: In this single-center trial, azelastine nasal spray was associated with reduced risk of SARS-CoV-2 respira …
Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
Klussmann JP, Grosheva M, Meiser P, Lehmann C, Nagy E, Szijártó V, Nagy G, Konrat R, Flegel M, Holzer F, Groß D, Steinmetz C, Scherer B, Gruell H, Schlotz M, Klein F, de Aragão PA, Morr H, Al Saleh H, Bilstein A, Russo B, Müller-Scholtz S, Acikel C, Sahin H, Werkhäuser N, Allekotte S, Mösges R. Klussmann JP, et al. Sci Rep. 2023 Apr 26;13(1):6839. doi: 10.1038/s41598-023-32546-z. Sci Rep. 2023. PMID: 37100830 Free PMC article. Clinical Trial.
Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. ...Comparable numbers of adverse events occurred in all treatment groups with …
Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days …
Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis.
Debbaneh PM, Bareiss AK, Wise SK, McCoul ED. Debbaneh PM, et al. Otolaryngol Head Neck Surg. 2019 Sep;161(3):412-418. doi: 10.1177/0194599819841883. Epub 2019 Apr 9. Otolaryngol Head Neck Surg. 2019. PMID: 30961435
OBJECTIVE: Combination therapy with intranasal azelastine and fluticasone propionate is an option for treatment of allergic rhinitis. This systematic review and meta-analysis examines existing literature to determine efficacy in treating allergic rhinitis compared to monot …
OBJECTIVE: Combination therapy with intranasal azelastine and fluticasone propionate is an option for treatment of allergic rhinitis. …
Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial.
Meiser P, Flegel M, Holzer F, Groß D, Steinmetz C, Scherer B, Jain R, Carvin-Ii Study Group. Meiser P, et al. Viruses. 2024 Dec 13;16(12):1914. doi: 10.3390/v16121914. Viruses. 2024. PMID: 39772221 Free PMC article. Clinical Trial.
A total of 39 (32.0%) subjects in the azelastine 0.1% treatment group and 40 (31.0%) subjects in the placebo group reported 48 and 51 adverse events, respectively. It is therefore concluded that azelastine 0.1% nasal spray is an efficacious, safe, and well-tolerated …
A total of 39 (32.0%) subjects in the azelastine 0.1% treatment group and 40 (31.0%) subjects in the placebo group reported 48 and 51 …
Second-generation antihistamines: a comparative review.
Slater JW, Zechnich AD, Haxby DG. Slater JW, et al. Drugs. 1999 Jan;57(1):31-47. doi: 10.2165/00003495-199957010-00004. Drugs. 1999. PMID: 9951950
This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofenadine, ketotifen, loratadine, mizolastine and terfenadine, for significant features that affect choice. ...
This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofen …
Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.
Sousa-Pinto B, Vieira RJ, Brozek J, Cardoso-Fernandes A, Lourenço-Silva N, Ferreira-da-Silva R, Ferreira A, Gil-Mata S, Bedbrook A, Klimek L, Fonseca JA, Zuberbier T, Schünemann HJ, Bousquet J. Sousa-Pinto B, et al. J Allergy Clin Immunol. 2024 Aug;154(2):340-354. doi: 10.1016/j.jaci.2024.04.016. Epub 2024 Apr 27. J Allergy Clin Immunol. 2024. PMID: 38685482 Free article.
Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the highest probability of resulting in moderate or large improve …
Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, …
Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis.
Lee TA, Pickard AS. Lee TA, et al. Pharmacotherapy. 2007 Jun;27(6):852-9. doi: 10.1592/phco.27.6.852. Pharmacotherapy. 2007. PMID: 17542768
In five comparisons of azelastine and placebo, azelastine was most efficacious, with a summary number needed to treat of 5.0 (95% confidence interval [CI] 3.3-10.0). ...No significant differences were observed between azelastine and active comparators for the …
In five comparisons of azelastine and placebo, azelastine was most efficacious, with a summary number needed to treat of 5.0 ( …
Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis.
Sousa-Pinto B, Vieira RJ, Bognanni A, Gil-Mata S, Ferreira-da-Silva R, Ferreira A, Cardoso-Fernandes A, Ferreira-Cardoso H, Marques-Cruz M, Duarte VH, Castro-Teles J, Campos-Lopes M, Teixeira-Ferreira A, Lourenço-Silva N, Chérrez-Ojeda I, Bedbrook A, Klimek L, Nuñez JJY, Zuberbier T, Fonseca JA, Schünemann HJ, Bousquet J; ARIA 2024 guideline panel. Sousa-Pinto B, et al. Allergy. 2025 Jan;80(1):94-105. doi: 10.1111/all.16384. Epub 2024 Nov 16. Allergy. 2025. PMID: 39548801
RESULTS: We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine-fluticasone, and fluticasone furoate were the most frequently highest-ranked interventions for efficacy outcomes, being regularly associated …
RESULTS: We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine- …
Onset of efficacy of azelastine hydrochloride 0.15% nasal spray for allergic rhinitis in an environmental exposure chamber.
Hsu SN, Sajjad F, Brigham E, Centofanti R, An R, Couroux P, Ng C. Hsu SN, et al. Ann Allergy Asthma Immunol. 2024 Dec;133(6):675-681. doi: 10.1016/j.anai.2024.07.020. Epub 2024 Jul 26. Ann Allergy Asthma Immunol. 2024. PMID: 39067509 Free article. Clinical Trial.
BACKGROUND: Azelastine nasal spray is effective in relieving symptoms of seasonal and perennial allergic rhinitis. ...The overall safety profile of azelastine has also been proven to be safe. These results, along with previous findings on efficacy and improved quali …
BACKGROUND: Azelastine nasal spray is effective in relieving symptoms of seasonal and perennial allergic rhinitis. ...The overall saf …
The efficiency of azelastine hydrochloride and fluticasone propionate nasal spray to improve PAP adherence in patients with obstructive sleep apnea.
Wongchan R, Tepwimonpetkun C, Kitsongsermthon J, Sapankaew T, Yotsombut K, Chittiwan W. Wongchan R, et al. Sci Rep. 2025 Apr 26;15(1):14601. doi: 10.1038/s41598-025-99548-x. Sci Rep. 2025. PMID: 40287492 Free PMC article. Clinical Trial.
This study aimed to assess the combined effectiveness of INS (fluticasone propionate) and intranasal antihistamines (azelastine hydrochloride) in enhancing CPAP adherence and mitigating CPAP-induced rhinitis symptoms in OSA patients. ...Although these drugs did not signifi …
This study aimed to assess the combined effectiveness of INS (fluticasone propionate) and intranasal antihistamines (azelastine hydro …
155 results